UYG:ARCA-ProShares Ultra Financials

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 44.37

Change

+0.81 (+1.86)%

Market Cap

USD 0.75B

Volume

0.15M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. FinancialsSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the financial services sector of the U.S. equity market. The fund is non-diversified.

Inception Date: 30/01/2007

Primary Benchmark: DJ US Financial TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 0.97%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-08-19 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing UYG

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.02% 89% A- 90% A-
Dividend Return 0.52% 32% F 11% F
Total Return 36.54% 89% A- 90% A-
Trailing 12 Months  
Capital Gain -0.60% 50% F 58% F
Dividend Return 1.03% 38% F 17% F
Total Return 0.42% 50% F 53% F
Trailing 5 Years  
Capital Gain 108.51% 82% B 92% A
Dividend Return 6.19% 70% C- 21% F
Total Return 114.70% 88% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 17.31% 87% B+ 90% A-
Dividend Return 18.18% 87% B+ 89% A-
Total Return 0.87% 56% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 26.08% 24% F 24% F
Risk Adjusted Return 69.70% 76% C+ 75% C
Market Capitalization 0.75B 95% A 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.